Navigation Links
Gene therapy extends survival in an animal model of spinal muscular atrophy
Date:5/22/2014

New Rochelle, NY, May 22, 2014To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords of animal models of SMA. A new study demonstrating that enough copies of the SMN1 gene can be delivered to the spinal cord motor neurons to extend the survival of the treated animals is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.

Marco Passini and coauthors from Genzyme (Framingham, MA), University of California San Francisco, Emory University School of Medicine (Atlanta, GA), and Georgetown University Medical Center (Washington, DC) used an adeno-associated viral vector as the delivery vehicle to transport copies of the SMN1 gene into motor neurons in the spinal cord via intrathecal delivery. They report on the effectiveness of restoring the levels of functional SMN protein in normal pig and non-human primate SMA models that would predict efficacy based on gene transfer with the same vector in an authentic mouse model of SMA in the article "Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9Survival Motor Neuron 1 for Spinal Muscular Atrophy."

"This is a very promising and thorough set of preclinical studies that supports rapid translation to the clinic," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>

Contact: Kathryn Ruehle
kruehle@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Novel RNAi therapy silences mutated Huntingtons disease gene and reduces symptoms
2. Phase I data suggest PLX3397 is a potential therapy for patients with advanced PVNS
3. Chemotherapy timing is key to success
4. Soy sauce molecule may unlock drug therapy for HIV patients
5. Autologous stem cell therapy improves motor function in chronic stroke victims
6. Loss of memory in Alzheimers mice models reversed through gene therapy
7. Radiation therapy for cervical cancer increases risk for colorectal cancer
8. Friedreichs ataxia -- an effective gene therapy in an animal model
9. New Penn-designed gel allows for targeted therapy after heart attack
10. Natural plant compounds may assist chemotherapy
11. Immunotherapy data heralds new era of lung cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy extends survival in an animal model of spinal muscular atrophy
(Date:2/11/2016)...  Vigilant Solutions announces today that its license plate recognition ... Lee,s Summit Police Department to improve ... of a homicide suspect. Kansas City ... square miles and is home to roughly 100,000 residents. ... mobile license plate reader system and also leverages Vigilant,s network ...
(Date:2/9/2016)... 9, 2016 Aware, Inc. (NASDAQ: AWRE ), a ... for its fourth quarter and year ended December 31, 2015.  ... fourth quarter of 2015 was $6.9 million, an increase of 61% ... income in the fourth quarter of 2015 was $2.6 million compared ... --> --> Higher revenue and operating ...
(Date:2/8/2016)... February 8, 2016 Worldcore ... which presents innovation for clients, comfort and unbeatable ... VoiceKey. --> Worldcore is the ... for clients, comfort and unbeatable security, with a ... Worldcore is the first EU-regulated ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ... December 31, 2015. --> --> ... net loss of $29.3 million, or $0.34 loss per share, compared ... share for the same period in 2014. For the year ended ... million, or $1.05 loss per share, as compared to a net ...
(Date:2/11/2016)...  Bioethics International, a not-for-profit organization focused on the ethics ... made accessible to patients around the world, today announced that ... publication of the Good Pharma Scorecard an ... as one of BMJ Open ,s ,Most Popular Articles, ... most frequently read. Ed Sucksmith , assistant editor ...
(Date:2/11/2016)... NY (PRWEB) , ... February ... ... a business-to-business publication dedicated to delivering cutting-edge information focused on the development ... Life Sciences to become a premier sponsor of the 2016 BioProcess International ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
Breaking Biology Technology: